Francisco J. Silva
Net Worth

Last updated:

What is Francisco J. Silva net worth?

The estimated net worth of Mr. Francisco J. Silva is at least $2,742,321 as of 9 Apr 2024. He owns shares worth $238,311 as insider, has earned $13,410 from insider trading and has received compensation worth at least $2,490,600 in BioRestorative Therapies, Inc..

What is the salary of Francisco J. Silva?

Mr. Francisco J. Silva salary is $207,550 per year as Vice President of R&D, Sec. and Director in BioRestorative Therapies, Inc..

How old is Francisco J. Silva?

Mr. Francisco J. Silva is 50 years old, born in 1975.

What stocks does Francisco J. Silva currently own?

As insider, Mr. Francisco J. Silva owns shares in one company:

Company Title Shares Price per share Total value
BioRestorative Therapies, Inc. (BRTX) Vice President of R&D, Sec. and Director 155,759 $1.53 $238,311

What does BioRestorative Therapies, Inc. do?

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

BRTX logo
BRTX
BioRestorative Therapies, Inc.
$1.53

Francisco J. Silva insider trading

BioRestorative Therapies, Inc.

Mr. Francisco J. Silva has made only one insider trade between 2013-2024, according to the Form 4 filled with the SEC. He purchased 6,600 units of BRTX stock worth $8,250 on 9 Apr 2024.

As of 9 Apr 2024 he still owns at least 155,759 units of BRTX stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 6,600 $1.25 $8,250
Purchase
Common Stock 1,232 $1.17 $1,441
Purchase
Common Stock 476 $1.13 $538
Purchase
Common Stock 4,954 $2.22 $10,998
Purchase
Common Stock 747 $3.56 $2,659
Purchase
Common Stock 943 $2.62 $2,467
Purchase
Common Stock 725 $3.39 $2,456
Purchase
Common Stock 806 $3.69 $2,973
Purchase
Common Stock 307 $3.32 $1,019
Purchase
Common Stock 2,816 $3.21 $9,048
Sale
Common Stock 3,958 $3.39 $13,410
Purchase
Common Stock 2,600 $3.35 $8,710
Purchase
Common Stock 4,000 $6.66 $26,628
Purchase
Common Stock 7,826 $6.73 $52,653
Purchase
Common Stock 20,955 $0.24 $4,987
Purchase
Common Stock 18,000 $0.27 $4,914
Purchase
Common Stock 7,500 $0.27 $2,025
Purchase
Common Stock 17,374 $0.26 $4,430
Purchase
Common Stock 1,800 $4.38 $7,884
Purchase
Common Stock 2,250 $4.25 $9,563
Purchase
Common Stock 20 $7.6 $152
Purchase
Common Stock 25 $7.6 $190
Purchase
Common Stock 100 $10.4 $1,040
Purchase
Common Stock 50 $10.4 $520

BioRestorative Therapies key executives

BioRestorative Therapies, Inc. executives and other stock owners filed with the SEC: